tweenvest

TRex Bio, Inc. (NasdaqGS: TRXB)

Health Care · Biotechnology · US

$14.10

-1.05% today · +0.7% 1Y

Public summary
A free snapshot of TRex Bio, Inc., with figures as of Nov 15, 2026. The full analysis is in the app.Open in the app

TRex Bio, Inc. (NasdaqGS: TRXB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $379.60M and employs 60 people.

Over the last twelve months the share price has gained 0.7%, trading between 12.99 and 16.56.

Tweenvest scores TRex Bio, Inc. across four factors: quality 64/100, value 69/100. Its strongest factor is value.

TRXB price history

Oct 9, 2026 · 14.00Weekly closes 13.26 – 14.10Nov 12, 2026 · 14.10

Key figures

Market cap
$379.60M
Revenue (TTM)
—
P/E
-120.74
EPS
-8.59
Dividend yield
—
Beta (5Y)
—
52-week high
$16.56
52-week low
$12.99
Avg volume (3M)
—
Shares outstanding
26.92M
Employees
60
Next earnings
—

About TRex Bio, Inc.

Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.

ISIN
US89531N1000
Founded
2018
Listed since
Oct 9, 2026
Exchange
Nasdaq Global Select
Currency
USD
CompanyMarket capPriceDay
Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687$386.54MCN¥15.41-1.85%
Opus Genetics, Inc.NasdaqCM: IRD$384.68M$3.98-1.97%
ARS Pharmaceuticals, Inc.NasdaqGM: SPRY$383.01M$3.81-3.54%
Avacta Group PlcAIM: AVCT$379.77M£0.59-4.22%
PureTech Health plcLSE: PRTC$378.25M£1.17-0.51%
Alector, Inc.NasdaqGS: ALEC$378.15M$2.54+3.67%
TransThera Sciences (Nanjing), Inc.SEHK: 2617$376.88MHK$7.26-4.16%
Puma Biotechnology, Inc.NasdaqGS: PBYI$373.26M$7.22+0.98%

Browse every Biotechnology company →